Key Points
Eli Lilly has sent cease-and-desist letters to hundreds of compounding pharmacies, telehealth companies, and medical spas making and selling compounded versions of tirzepatide..
Tirzepatide, the active ingredient in Eli Lillys diabetes drug Mounjaro and weight-loss medication Zepbound, was on the US Food and Drug Administrations shortage list from December 2022 until October 2, 2024..
Eli Lilly also targeted at least one weight-loss clinic promoting its tirzepatide products on Reddit, which has several active communities devoted to compounded GLP-1 medications...
Shortly after the shortage ended, a compounding trade group called the Outsourcing Facilities Association filed a lawsuit in a Texas federal court against the FDA, claiming that tirzepatide remains in short supply and that the decision to officially end the shortage is abruptly depriving patients of a much-needed treatment and artificially raising drug prices...
Meanwhile, although Novo Nordisks GLP-1 drugs remain in shortage, the company has recently pushed against compounded semaglutide by publishing a peer-reviewed article in the journal Pharmaceutical Research examining clinical testing of 26 samples of compounded semaglutide..
You might be interested in
A Major GLP-1 Drug Shortage Is Over. Some Patients Aren’t Celebrating
12, Oct, 24Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded versions of these GLP-1 medications, it’s a complicated situation.